Last reviewed · How we verify
decitabine injection
Decitabine is a DNA methyltransferase inhibitor that reduces DNA methylation, reactivating silenced tumor suppressor genes and promoting differentiation and apoptosis in myelodysplastic cells.
Decitabine is a DNA methyltransferase inhibitor that reduces DNA methylation, reactivating silenced tumor suppressor genes and promoting differentiation and apoptosis in myelodysplastic cells. Used for Myelodysplastic syndromes (MDS), Acute myeloid leukemia (AML).
At a glance
| Generic name | decitabine injection |
|---|---|
| Also known as | Decitabine, ASTX 727, tirelizumab, decitabine, DEC |
| Sponsor | Janssen Korea, Ltd., Korea |
| Drug class | DNA methyltransferase inhibitor |
| Target | DNA methyltransferase (DNMT) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Decitabine is a cytidine analog that inhibits DNA methyltransferase (DNMT), leading to hypomethylation of DNA. By reducing aberrant DNA methylation in myelodysplastic syndrome cells, it reactivates epigenetically silenced tumor suppressor genes, promoting cellular differentiation, growth arrest, and apoptosis. This mechanism restores normal gene expression patterns in dysplastic hematopoietic cells.
Approved indications
- Myelodysplastic syndromes (MDS)
- Acute myeloid leukemia (AML)
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia, anemia)
- Infection
- Nausea and vomiting
- Fatigue
- Diarrhea
- Constipation
Key clinical trials
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (PHASE2)
- A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia (PHASE1)
- Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia (PHASE1)
- Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia (PHASE2)
- Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia (PHASE1)
- Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCL (PHASE1, PHASE2)
- Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients (PHASE2)
- A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- decitabine injection CI brief — competitive landscape report
- decitabine injection updates RSS · CI watch RSS
- Janssen Korea, Ltd., Korea portfolio CI